Depression Associated Articles & Analysis
8 news found
Our Risk-based analytics engine can find members with, for example, high-predicted probability of substance use disorder or depression, but no associated diagnosis in existing health records. This technology helps drive Ontrak's impressive member outreach success of 54% across all lines of business, which Ontrak believes is more than double the industry standard. ...
In today’s fast-paced and stressful society, the prevalence of anxiety and depression has become a significant concern. Emotion-related animal behavior tests aim to provide a good research tool for the study of emotion-associated diseases. Anxiety and depression affect millions of individuals worldwide, leading to a significant burden on ...
We believe the preliminary data from these early animal studies of NES100 support our belief that Envelta™ may have comparable preclinical activity to morphine in all animal pain models tested without the drug seeking, respiratory depression, and tolerance associated with opioids. Currently, enkephalins are limited in their therapeutic potential by their ...
Zuranolone is an investigational therapy being evaluated as a once-daily, 14-day oral short course treatment in adults with major depressive disorder (MDD) and PPD. The SKYLARK Study, as previously reported, achieved the primary and all key secondary endpoints, with study participants demonstrating rapid and significant improvements in depressive symptoms as ...
Up to 36% of patients1 are at high risk of post-operative respiratory depression which is associated with increased risk of in-hospital mortality, increased length of stay and higher cost. ...
Kapruvia® will be the first therapy available in Europe for the treatment of CKD-associated pruritus in hemodialysis patients. “We are very excited about the European Commission’s approval of Kapruvia®, marking an important milestone on our journey to advance and fundamentally change the treatment paradigm for people living with the severe burden of pruritus ...
The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. ...
Food and Drug Administration in August 2021 for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. ...